Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2012 | |
| Cash Flows From Operating Activities | |
| Net Income | 17,730 |
| Depreciation Amortization | 40 |
| Other Working Capital | 31,450 |
| Other Operating Activity | 2,740 |
| Operating Cash Flow | $51,960 |
| Cash Flows From Investing Activities | |
| PPE Investments | -20 |
| Investing Cash Flow | $-20 |
| Cash Flows From Financing Activities | |
| Other Financing Activity | 7,900 |
| Financing Cash Flow | $7,900 |
| Beginning Cash Position | 3,110 |
| End Cash Position | 62,950 |
| Net Cash Flow | $59,840 |
| Free Cash Flow | |
| Operating Cash Flow | 51,960 |
| Free Cash Flow | 51,960 |